Novel 18F-Labeled PET-Tracers for Use in Treatment of Neurological Disorders
Novel 18F-labeled GSK3β inhibitors that can cross the blood brain barrier. Background: Dysregulation of Glycogen Synthase Kinase 3β (GSK3β) is associated with several neurodegenerative diseases, such as Parkinson’s, Alzheimer’s and Huntington’s. Therefore, development of a selective GSK3β PET tracer would enable...
Published: 3/20/2024
|
Inventor(s): Ming-Yu Ngai, Katarzyna Lee, Kongzhen Hu *credit to use, Neil Nasdev, Stephen Haggarty
Keywords(s): Technologies
Category(s): Campus > Stony Brook University, Technology Classifications > Drug Design and/or Synthesis, Technology Classifications > Diagnostics, Technology Classifications > Therapeutics
|